Diaverum’s Global Director of Patient Experience and Stakeholder Management, Michaela Blomstrand, recently had the pleasure of joining a key event in Sweden’s healthcare sector - the presentation of Swecare’s Health Export Barometer 2025, a report on the development of Sweden’s health sector exports.
Held in Stockholm, the event included a panel discussion around the report and featured inspiring, thought-provoking talks by Håkan Jevrell, State Secretary, Ministry for Foreign Affairs, and Acko Ankarberg Johansson, Minister of Health and Social Affairs.
The Swedish health, or life sciences sector is one of the country’s largest export categories and a key driver of growth & innovation. The products, services, and innovations developed by Swedish companies not only help ensure high-quality healthcare in Sweden but also improve access to and the quality of healthcare globally.
As an organisation committed to delivering life-enhancing renal care to patients worldwide, Diaverum shares the same vision as Swecare – delivering and broadening access to the highest quality of care. For this reason, we were proud to have Michaela join the Board of Swecare last year, that together with Swecare’s Management team, are responsible for shaping the strategy and direction of the organisation’s work in promoting the country’s life sciences industry.
About Swecare’s Health Export Barometre
Released for the sixth consecutive year, Swecare’s Health Export Barometer is an annual report that compiles and analyses information on Swedish health exports. The report is based on export data from Statistics Sweden (SCB), a survey answered by Swecare’s member companies, and interviews with representatives from the government, businesses, university hospitals, & industry organisations within the health sector. The aim is to highlight the health sector’s significant contribution to the Swedish economy and the conditions necessary for continued strong growth.
The key takeaways from the 2025 report are:
- Sweden’s healthcare sector remains strong: despite a slight decline in exports, pharmaceuticals remain Sweden’s second-largest export category, accounting for over seven percent of total exports, highlighting the industry's importance for the economy and employment.
- There is high global demand for Swedish solutions: the need for healthcare and life science products remains high worldwide, and Swedish companies are well-positioned to capitalise on this demand, despite increasing competition.
- A strong ecosystem is important: life science plays a crucial role in strengthening Sweden’s competitiveness. By fostering collaboration between academia, industry, and the technology sector, Sweden can continue driving innovation and economic growth.
In addition to participating in the event, Diaverum was invited to feature in the report, as a successful example of an exporting/global care provider. You can view the full report here (content in Swedish).
Michaela had this to say about the event: “I was delighted to participate in the event and exchange insights with my fellow peers about Sweden’s healthcare sector & how we can strengthen the position of Swedish life sciences globally.”
Sweden is widely recognised for its strong foundation in life sciences, supported by world-class research institutions, a robust healthcare system, and innovative companies. We will continue to support Swecare's excellent work, collaborating closely to ensure that Sweden and its healthcare businesses continue to play a leading role in shaping the global life sciences landscape, not only for the benefit of national stakeholders and businesses, but more importantly, for people around the world”.